<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03171831</url>
  </required_header>
  <id_info>
    <org_study_id>Guangxi-Haplo-HSCT-2016</org_study_id>
    <nct_id>NCT03171831</nct_id>
  </id_info>
  <brief_title>Haploidentical Hematopoietic Stem Cell Transplantation for Patients With Thalassemia Major</brief_title>
  <official_title>Haploidentical Hematopoietic Stem Cell Transplantation for Patients With Thalassemia Major</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>First Affiliated Hospital of Guangxi Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>First Affiliated Hospital of Guangxi Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to assess the safety and efficacy of haploidentical hematopoietic
      stem cell transplantation for patients with thalassemia major.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The only curative therapy for thalassemia major remains the replacement of the defective
      erythropoiesis by allogeneic hematopoietic stem cell transplantation(HSCT). However, this
      option is unavailable to many patients as a result of a lack of compatible
      donors.Haploidentical transplantation has been certified as a valuable alternative for
      hematological malignancy patients lacking a well-matched donor, with results comparable
      matched HLA-identical sibling donors or unrelated donors.The objective of this study is to
      test the feasibility of haploidentical HSCT for patients with thalassemia major.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2017</start_date>
  <completion_date type="Anticipated">April 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>2 years</time_frame>
    <description>2-years overall survival</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease Free Survival</measure>
    <time_frame>2 years</time_frame>
    <description>2-years disease free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Engraftment</measure>
    <time_frame>30 days</time_frame>
    <description>Myeloid engraftment at day +30</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transplant Related Mortality</measure>
    <time_frame>1 year</time_frame>
    <description>Transplant-related mortality by 1 year</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative Incidence of acute Graft Versus Host Disease</measure>
    <time_frame>180 days</time_frame>
    <description>Acute graft versus host disease at day +180</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative Incidence of chronic Graft Versus Host Disease</measure>
    <time_frame>2 years</time_frame>
    <description>Chronic graft versus host disease by 2 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative Incidence of Infectious Complications</measure>
    <time_frame>2 years</time_frame>
    <description>Cumulative incidence of bacterial, fungal and viral infections by 2 years</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Thalassemia Major</condition>
  <arm_group>
    <arm_group_label>Haploidentical HSCT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Procedure: Haploidentical hematopoietic stem cell transplantation from a related donor (partially matched sibling, father or mother).
Conditioning: Busulfan （4 mg/kg/day,4 days） + Cyclophosphamide （50 mg/kg/day,4 days）+ Fludarabine （50 mg/m2/day,3 days）
GVHD Prophylaxis：Mycophenolate mofetil（0.25g/day）+ Tacrolimus（0.03mg/kg/day）+ Methotrexate（15mg/m2 on day +1,10mg/m2 on day +3,+6,+11）+ Thymoglobulin（2.5 mg/kg/day,4 days）+Basiliximab（10mg on day 0 and +4）</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Busulfan</intervention_name>
    <description>Busulfan（4 mg/kg/day,4 days）</description>
    <arm_group_label>Haploidentical HSCT</arm_group_label>
    <other_name>Bu</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Cyclophosphamide（50 mg/kg/day,4 days）</description>
    <arm_group_label>Haploidentical HSCT</arm_group_label>
    <other_name>Cy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>Fludarabine（50 mg/m2/day,3 days）</description>
    <arm_group_label>Haploidentical HSCT</arm_group_label>
    <other_name>Flu</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate mofetil</intervention_name>
    <description>Mycophenolate mofetil（0.25g/day）</description>
    <arm_group_label>Haploidentical HSCT</arm_group_label>
    <other_name>MMF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>Tacrolimus（0.03mg/kg/day）</description>
    <arm_group_label>Haploidentical HSCT</arm_group_label>
    <other_name>FK506</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>Methotrexate（15mg/m2 on day +1,10mg/m2 on day +3,+6,+11）</description>
    <arm_group_label>Haploidentical HSCT</arm_group_label>
    <other_name>MTX</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thymoglobulin</intervention_name>
    <description>Thymoglobulin（2.5 mg/kg/day,4 days）</description>
    <arm_group_label>Haploidentical HSCT</arm_group_label>
    <other_name>ATG</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Basiliximab</intervention_name>
    <description>Basiliximab（10mg on day 0 and +4）</description>
    <arm_group_label>Haploidentical HSCT</arm_group_label>
    <other_name>Simulect</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Diagnosed with thalassemia major

          2. Lacking of a HLA-identical sibling donor or unrelated donor

          3. Indication of haploidentical hematopoietic stem cell transplantation

          4. No restrictions for transplantation

        Exclusion Criteria:

          1. Any restriction for transplantation

          2. No indication of haploidentical hematopoietic stem cell transplantation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yongrong Lai, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>First Affiliated Hospital of Guangxi Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yongrong Lai, MD</last_name>
    <phone>+86（0771）5356510</phone>
    <email>laiyongrong@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Meiqing Wu, MD</last_name>
    <phone>+86（0771）5356510</phone>
    <email>wumeiqing1309@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>First Affiliated Hospital of Guangxi Medical University</name>
      <address>
        <city>Nanning</city>
        <state>Guangxi</state>
        <zip>510515</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yongrong Lai, MD</last_name>
      <phone>+86（0771）5356510</phone>
      <email>laiyongrong@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 18, 2017</study_first_submitted>
  <study_first_submitted_qc>May 27, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 31, 2017</study_first_posted>
  <last_update_submitted>May 27, 2017</last_update_submitted>
  <last_update_submitted_qc>May 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>First Affiliated Hospital of Guangxi Medical University</investigator_affiliation>
    <investigator_full_name>Yongrong Lai</investigator_full_name>
    <investigator_title>Director of the Hematology Department</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thalassemia</mesh_term>
    <mesh_term>beta-Thalassemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Thymoglobulin</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
    <mesh_term>Basiliximab</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

